TuHURA Biosciences Files 8-K

Ticker: HURA · Form: 8-K · Filed: Nov 25, 2025 · CIK: 1498382

Sentiment: neutral

Topics: 8-K, disclosure, company-name-change

TL;DR

TuHURA Bio filed an 8-K on Nov 25, 2025. Check for Reg FD updates.

AI Summary

TuHURA Biosciences, Inc. (formerly Kintara Therapeutics, Inc.) filed an 8-K on November 25, 2025, reporting a Regulation FD Disclosure. The company, incorporated in Nevada with its principal executive offices in Tampa, Florida, is in the Pharmaceutical Preparations industry.

Why It Matters

This filing indicates a formal disclosure event by TuHURA Biosciences, Inc. to the SEC, which could contain material information relevant to investors.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for a Regulation FD disclosure, which is routine and does not inherently signal high risk.

Key Numbers

Key Players & Entities

FAQ

What specific information is being disclosed under Regulation FD?

The filing is a Form 8-K reporting a Regulation FD Disclosure, but the specific content of the disclosure is not detailed in the provided header information.

When was TuHURA Biosciences, Inc. formerly known as Kintara Therapeutics, Inc.?

The date of the name change from Kintara Therapeutics, Inc. to TuHURA Biosciences, Inc. was August 20, 2020.

Where are TuHURA Biosciences, Inc.'s principal executive offices located?

The principal executive offices are located at 10500 University Center Dr., Suite 110, Tampa, Florida 33612.

What is TuHURA Biosciences, Inc.'s Standard Industrial Classification (SIC) code?

The SIC code for TuHURA Biosciences, Inc. is 2834, which corresponds to Pharmaceutical Preparations.

What is the exact date of this 8-K filing?

The 8-K filing is dated November 25, 2025.

Filing Stats: 678 words · 3 min read · ~2 pages · Grade level 13.5 · Accepted 2025-11-25 08:01:48

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TUHURA BIOSCIENCES, INC. Date: November 25, 2025 By: /s/ Dan Dearborn Name: Dan Dearborn Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing